Skip to main content

Table 2 Clinicopathological characteristics of the sarcomatous component of carcinosarcoma and the status of intratumoral stromal CD3, CD4, CD8, FOXP3, PD-1, PD-L1 and PD-L2 (N = 57)

From: The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma

Clinicopathological features Total no. of cases CD3_S CD4_S CD8_S FOXP3_S PD-1_S PD-L1_S PD-L2_S
Low High p-value Low High p-value Low High p-value Low High p-value Low High p-value Low High p-value Low High p-value
Age N = 57    
 <  60 17 14 3 0.503 8 9 0.124 3 14 0.795 14 3 0.924 12 5 0.827 10 7 0.118 14 3 0.924
 ≥ 60 40 37 3 19 11 10 30 35 5 31 9 33 7 35 5
Stage N = 57
 I/II 15 12 3 0.367 11 4 0.631 5 10 0.439 12 3 0.732 10 5 0.569 10 5 0.569 13 2 1.000
 III/IV 42 39 3 26 16 8 34 37 5 33 9 33 9 36 6
Histological subtype N = 42
 Heterologous 30 28 2 0.909 22 8 0.957 7 23 0.418 25 5 0.834 24 6 0.647 25 5 1.000 27 3 0.940
 Homologous 12 12 0 8 4 5 7 11 1 11 1 10 2 10 2
LVI N = 41
 Present 25 21 4 0.252 14 11 0.625 3 22 0.266 20 5 0.844 17 8 0.567 18 7 0.434 21 4 0.760
 Absent 16 16 0 11 5 5 11 14 2 13 3 14 2 12 4
  1. Differences in absolute value correspond to missing data. Significant P-values are emboldened
  2. LVI Lymphovascular Invasion, S Sarcomatous Component, ER Estrogen Receptor, PR Progesterone Receptor, CD3 Cluster of Differentiation 3, CD4 Cluster of Differentiation 4, CD8 Cluster of Differentiation 8, FOXP3 Forkhead Box P3, PD-1 Programmed Cell Death Protein 1, PD-L1 Programmed Death-Ligand 1, PD-L2 Programmed Death-Ligand 2